Providing Support and Funding Research

Welcome to The Vision For Tomorrow Foundation!

The Vision For Tomorrow Foundation provides support and information on albinism and aniridia, two conditions causing low vision from birth.  We invite you to explore our website to learn more about albinism and aniridia.  We welcome you to meet some of our members and families profiled throughout the website who are leading fulfilling lives.  If you need support in your journey through albinism or aniridia, we encourage you to reach out to us by either contacting us via Facebook, email, or going to the ‘Contact Us’ section of the website for other options.  We are here to support you!

The Vision For Tomorrow Foundation also funds research into treatments and cures for ocular complications common in people living with albinism and aniridia.  Funding research is at the heart of our foundation. Research makes it possible to better understand and more effectively treat ocular complications common in albinism and aniridia. It allows us to envision a world where their vision problems may be cured — or even prevented. We are proud to say that over 95% of the funds raised by Vision For Tomorrow are directly invested in research projects!  We understand that by investing in research today, we will build a brighter future.

Comments are closed.

Family Perspectives

Latest News

    May 7, 2015 (Denver, Col) – In December 2013, The Vision for Tomorrow Foundation proudly announced the funding of the first clinical trial based on START Therapy, which was developed Dr. Cheryl Gregory-Evans, PhD and Dr. Kevin Gregory Gregory-Evans MD PhD at the University of British Columbia. Following some initial delays, the researchers leading the trial along with PTC Therapeutics confirmed at The Association for Research and Vision in Ophthalmology (ARVO) annual meeting this week that the human clinical study would begin later this year. The proof-of-concept study has been revised based on the current FDA approvals for the drug being used...
  • VFT Funds Ground-Breaking Clinical Trial for Aniridia
    December, 2013.  The Vision For Tomorrow Foundation is proud to announce the funding of a clinical trial for START Therapy, a first-ever pharmaceutical topical therapy for patients with aniridia caused by a PAX6 nonsense mutation.  START Therapy was developed Dr. Cheryl Gregory-Evans, PhD and Dr. Kevin Gregory Gregory-Evans MD PhD at the University of British Columbia.  Drs. Gregory-Evans’ ground-breaking study on aniridic mice, to be published in the December 2013 issue of the Journal of Clinical Investigation, shows that the application of the START Therapy drop not only halted disease progression but also reversed corneal, lens, and retinal malformation defects...